



Medicine Supply Notification

MSN/2023/053U

UPDATE to communication (MSN/2023/053) issued on 24 May 2023 in **bold**.

Tresiba® (insulin degludec) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens

Tier 2 – medium impact*

Date of issue: 10/12/2025

Link: [Medicines Supply Tool](#)

Summary

- **Tresiba® FlexTouch® (insulin degludec) 100units/ml pens have been discontinued. Supplies were exhausted in July 2023.**
- Tresiba® Penfill® (insulin degludec) 100units/ml solution for injection 3ml cartridges remain available and can support increased demand.

Actions Required

Prescribers should:

- not initiate new patients on Tresiba® FlexTouch® 100units/ml pens;
- consider prescribing Tresiba® Penfill® cartridges, which are able to support the market, taking into account the patient's manual dexterity and ability to use the new device correctly;
- when prescribing Tresiba® Penfill® cartridges, ensure that the patient is prescribed a Novo Nordisk insulin delivery system and appropriate needles (see Supporting information);
- seek advice from specialist diabetes team on use of an alternative insulin, if the above option is not considered suitable; and
- ensure that all patients initiated on a new device are counselled on the change in device, and provided with training on their use, including signposting to training videos (see Supporting information), as well as potential need for closer monitoring of blood glucose levels.

Pharmacists and dispensing doctors should:

- ensure that all patients presenting with a new prescription for Tresiba® Penfill® cartridges have access to an appropriate device and needles, and can use the device correctly (see Supporting information); and
- ensure that all patients are counselled on the change in device and the potential need for closer monitoring of blood glucose levels during this time.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Insulin degludec is a once-daily ultra-long-acting basal insulin licensed for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.

In NICE guidance on use of long-acting insulin for type 1 diabetes in adults, insulin degludec (100 units/ml) is suggested as an alternative basal insulin therapy to twice-daily insulin detemir if there is a particular concern about nocturnal hypoglycaemia or if people need help from a carer or healthcare professional to administer injections. Once-daily insulin glargine (100 units/ml) is another recommendation if insulin detemir is not tolerated or the person has a strong preference for once-daily basal injections.

Counselling points for clinicians, dispensing doctors and pharmacists

- Tresiba® Penfill® cartridges can be used with the NovoPen® 6 and NovoPen Echo® Plus devices.
- It should be noted that Tresiba® FlexTouch® U100 pens are calibrated to adjust the dose in 1 unit increments and:
 - NovoPen® 6 dials in 1 unit increments
 - NovoPen Echo® Plus dials in ½ unit increments.
- Ensure that patients have access to a suitable device and that the patient is thoroughly counselled on how to use this device. Further information can be found from the links below:
 - [Smart insulin pens - JDRF, the type 1 diabetes charity](#)
 - [NOVOPEN® 6 and NOVOPEN ECHO® PLUS resources](#)

Further information

[SmPC for Tresiba® FlexTouch® U100 pens](#)

[SmPC for Tresiba® Penfill® cartridges](#)

[BNF Insulin degludec](#)

[BNF: Insulin preparations](#)

[Novo Nordisk quick guide to using NovoPen® 6 or NovoPen Echo® Plus](#)

[NICE guidance: Type 1 diabetes in adults \(insulin therapy\)](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.